Recent research have focused on the intersection of glucagon-like peptide-1|GIP|GCGR stimulant therapies and dopaminergic communication. While GLP agonists are commonly employed for managing type 2 diabetes mellitus, their unexpected impacts on reinforcement circuits, specifically mediated by dopaminergic pathways, are receiving considerable intere